PT  - JOURNAL ARTICLE
AU  - Yuichi Saito
AU  - Atsushi Tanaka
AU  - Yuji Koide
AU  - Hisako Yoshida
AU  - Daigaku Uchida
AU  - Kazuo Matsunaga
AU  - Naoto Yokota
AU  - Chikara Ueyama
AU  - Yoshio Kobayashi
AU  - Koichi Node
ED  - ,
TI  - Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study
AID  - 10.1136/rmdopen-2022-002505
DP  - 2022 Sep 01
TA  - RMD Open
PG  - e002505
VI  - 8
IP  - 2
4099  - http://rmdopen.bmj.com/content/8/2/e002505.short
4100  - http://rmdopen.bmj.com/content/8/2/e002505.full
SO  - RMD Open2022 Sep 01; 8
AB  - Objectives Although uric acid lowering therapies, including xanthine oxidase (XO) inhibition, may reduce the absolute level of blood pressure (BP), the effect of XO inhibition on BP variability is largely unknown. The aim of the present analysis was to evaluate the impact of febuxostat, an XO inhibitor, on BP variability in a randomised trial setting.Methods This was a subanalysis of the PRIZE Study, a randomised trial to evaluate the potential effect of febuxostat on carotid intima–media thickness progression. Patients with hyperuricemia and carotid plaques were randomly assigned to the febuxostat or control group. During a 24-month period, office BP and pulse rate (PR) were measured ≥3 times. BP and PR variabilities were assessed with SD and coefficient of variation (CV). The effect of febuxostat on BP and PR variabilities was adjusted with age, sex and baseline BP or PR, expressed with 95% CIs.Results A total of 472 patients were included into the present subanalysis. During the 24-month follow-up period, the febuxostat group had a significantly lower adjusted mean systolic BP (128.4 (126.8–130.0) vs 130.7 (129.1–132.2) mm Hg, p=0.04) and CV of systolic BP (7.4 (6.7–8.0) vs 8.2 (7.6–8.8), p=0.04) than the control group. Adjusted SD of PR was also lower in the febuxostat group than their counterpart (5.95 (4.93–6.97) vs 7.33 (6.32–8.33), p=0.04).Conclusion XO inhibition with febuxostat was associated with reduced visit-to-visit BP variability as well as reduced PR variability in patients with hyperuricemia and carotid plaques.Trial registration numbers University Hospital Medical Information Network Clinical Trial Registry (UMIN000012911 and UMIN000041322).No data are available.